Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

132.36
+1.721.32%
Volume:133.34K
Turnover:17.50M
Market Cap:13.28B
PE:28.34
High:132.48
Open:129.12
Low:129.09
Close:130.64
52wk High:160.18
52wk Low:84.23
Shares:100.36M
Float Shares:98.00M
Volume Ratio:0.64
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.67
EPS(LYR):4.67
ROE:16.38%
ROA:9.53%
PB:4.08
PE(LYR):28.34

Loading ...

Does Strong Q4 Results And INGREZZA Guidance Change The Bull Case For Neurocrine Biosciences (NBIX)?

Simply Wall St.
·
Yesterday

Neurocrine Biosciences to Present at TD Cowen Annual Health Care Conference and Leerink Global Healthcare Conference

Reuters
·
Feb 25

Neurocrine Initiated at Outperform by Wolfe Research

Dow Jones
·
Feb 24

Neurocrine (NBIX) Receives a Buy from RBC Capital

TIPRANKS
·
Feb 24

Neurocrine initiated with an Outperform at Wolfe Research

TIPRANKS
·
Feb 24

Neurocrine (NBIX) Gets a Buy from Guggenheim

TIPRANKS
·
Feb 18

Neurocrine Is Maintained at Buy by Truist Securities

Dow Jones
·
Feb 18

Neurocrine price target lowered to $140 from $169 at Truist

TIPRANKS
·
Feb 17

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Neurocrine (NBIX) and Dexcom (DXCM)

TIPRANKS
·
Feb 17

Neurocrine Biosciences (NBIX) Is Down 12.1% After Issuing 2026 INGREZZA Sales Guidance - What's Changed

Simply Wall St.
·
Feb 14

UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating

MT Newswires Live
·
Feb 14

Nxera Pharma Unveils Corporate Presentation Highlighting Global Strategy and Drug Discovery Platform

Reuters
·
Feb 13

Neurocrine Biosciences Earnings Call Highlights Growth Momentum

TIPRANKS
·
Feb 13

Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance

Benzinga
·
Feb 13

Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says

MT Newswires Live
·
Feb 13

Neurocrine (NBIX) Receives a Buy from Jefferies

TIPRANKS
·
Feb 12

Stock Track | Neurocrine Biosciences Plummets 5.65% Intraday Amid Series of Analyst Price Target Reductions

Stock Track
·
Feb 12

Wedbush Remains a Buy on Neurocrine (NBIX)

TIPRANKS
·
Feb 12

Canaccord Genuity Reaffirms Their Buy Rating on Neurocrine (NBIX)

TIPRANKS
·
Feb 12

Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $175, Keeps Equalweight Rating

MT Newswires Live
·
Feb 12